Overview

A Study Of Oral GW572016 In Advanced Or Metastatic Non-Small Cell Lung Cancer

Status:
Terminated
Trial end date:
2008-07-01
Target enrollment:
Participant gender:
Summary
This study was designed to evaluate and compare the efficacy of two dose schedules of an oral investigational drug for the treatment of advanced or metastatic non-small cell lung cancer.
Phase:
Phase 2
Details
Lead Sponsor:
GlaxoSmithKline
Treatments:
Lapatinib